Rhythm Pharmaceuticals Inc (RYTM)

Form 8-K - Current report

Form 8-K - Current report

Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Setmelanotide therapy achieved robust, sustained and clinically significant weight loss in patients with...

 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI...

Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome

BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026

BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global...

Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics

BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global...

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global...

Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology

– Real world data showed clinically meaningful BMI reductions with setmelanotide in 62 adults with 12-month...

Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference

BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report